Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d -Aspartate Receptors
- 31 May 2000
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 163 (1) , 239-243
- https://doi.org/10.1006/exnr.2000.7374
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated RatExperimental Neurology, 1999
- CP‐101,606: An NR2B‐Selective NMDA Receptor AntagonistCNS Drug Reviews, 1998
- Antinociceptive activity of CP‐101,606, an NMDA receptor NR2B subunit antagonistBritish Journal of Pharmacology, 1997
- Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidium in basal ganglia circuitryBrain Research Reviews, 1995
- Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's diseaseAnnals of Neurology, 1994
- Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1993
- Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonismMovement Disorders, 1991
- Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's diseaseTrends in Neurosciences, 1990
- The functional anatomy of basal ganglia disordersTrends in Neurosciences, 1989
- Extracellular levels of amino acids in striatum and globus pallidus of 6-hydroxydopamine-lesioned rats measured with microdialysisActa Physiologica Scandinavica, 1986